ROIVW (Roivant Sciences) Short Percentage of Float


ROIVW Roivant Sciences Ltd ROIVW
55 GF Score
Price $2.75
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ROIVW vs INSM, INCY, BNTX: Short Percentage of Float Comparison

For the Biotechnology subindustry, Roivant Sciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roivant Sciences Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Short Percentage of Float falls into.


ROIVW
55GF Score
Roivant Sciences Ltd ROIVW
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for ROIVW

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.75
Price